ERIC WOBUDEYA
ID: UNCST-2019-R001047
|
Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV
REFNo: HS6555ES
Primary Objectives
Cohort 1 and Cohort 2
• To determine the weight-band dosing of RPT taken as part of the 1HP regimen by evaluating:
⎯ PK RPT exposures among children with and without HIV
⎯ Safety and tolerability of the 1HP regimen among children with HIV while receiving twice-daily DTG and children without HIV through 28 days of dosing
Cohort 2
• To evaluate the effect of RPT taken as part of the 1HP regimen on the PK of DTG
Secondary Objectives
Cohort 1 and Cohort 2
• To evaluate the effect of covariates including age, weight, sex, ethnicity, nutritional status, and HIV-1 status on the PK of RPT taken as part of the 1HP regimen
• To evaluate the safety of the 1HP regimen through 24 weeks of follow-up
• To evaluate the palatability and acceptability of the 1HP regimen
• To evaluate adherence to the 1HP regimen
Cohort 2
• To evaluate the safety and tolerability of twice-daily DTG through 42 days among children with HIV who are receiving 1HP
• To evaluate virologic control (less than 200 copies/mL) at Day 42 among children taking a DTG-based ARV treatment regimen co-administered with 1HP
|
Kampala, mulago
|
Uganda |
2025-11-04 12:59:17 |
2028-11-04 |
40 |
children living without HIV (Cohort 1) and children living with HIV (Cohort 2) at risk of TB disease who are less than 13 years of age. |
National Institute of Allergy and Infectious Diseases Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute of Mental Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Henry Mugerwa
ID: UNCST-2019-R000420
|
A5402 An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV
REFNo: HS6604ES
1.2 Primary Objectives
1.2.1 To compare pramipexole to escitalopram in the treatment of MDD (and comorbid MDD with MND) based on the Beck Depression Inventory-II (BDI-II/BDI-2) total score [Beck 1996] from baseline to week 24.
1.2.2 To evaluate the safety of pramipexole and escitalopram in PWH having MDD (and comorbid MDD with MND) from baseline to week 24.
1.3 Secondary Objectives
1.3.1 To compare pramipexole to escitalopram in the treatment of MDD using MDD caseness, neurocognitive outcomes, and functional status from baseline to week 24.
1.3.2 To compare the depression, neurocognitive, and functional status outcomes in PWH with MDD alone and with comorbid MDD with MND treated with pramipexole versus escitalopram from baseline to week 24.
1.3.3 To compare the impact of pramipexole and escitalopram on all outcomes above by female versus male sex (assigned at birth) from baseline to week 24.
1.3.4 To determine the impact of pramipexole compared to escitalopram on the measure of HIV-1 RNA viral load in the peripheral blood.
1.4 Exploratory Objectives
1.4.1 To characterize associations between escitalopram trough concentrations and treatment efficacy (BDI-II/BDI-2 total score) as well as participant adverse events (adverse event frequency, severity, and discontinuation rates).
1.4.2 To characterize associations between escitalopram trough concentrations and genetic polymorphisms that affect metabolizing enzymes of escitalopram (known metabolizing enzymes include CYP2C19, CYP2D6, and CYP3A4).
1.4.3 To explore associations between cerebrospinal fluid (CSF) concentrations of escitalopram and BDI-II/BDI-2 total score.
1.4.4 To evaluate adverse events potentially related to drug interactions between antiretroviral therapy (ART) and escitalopram and pramipexole, respectively.
1.5 Substudy Objective
1.5.1 CSF Substudy
To compare the impact of pramipexole and escitalopram on biomarker outcomes in a CSF substudy of participants with MDD alone.
|
|
Uganda |
2025-10-29 16:04:25 |
2028-10-29 |
50 |
PWH having a diagnosis of MDD alone or with comorbid MDD and MND
· ≥18 to ≤70 years old both male and female.
People who understand English and Luganda because the site informed consent forms only in Luganda and English |
National Institute of Allergy and Infectious Diseases and CIPLA |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Abel Kakuru
ID: UNCST-2022-R009193
|
Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the prevention of febrile illnesses in children with sickle cell anemia: a double-blind randomized controlled trial
REFNo: HS6294ES
1.
To compare the incidence of all-cause febrile illness among children with sickle cell anemia randomized to receive monthly SP vs. monthly DP+SP.
2.
To compare the incidence of adverse events among children with sickle cell anemia randomised to receive monthly SP vs. monthly DP+SP.
3.
To compare the prevalence of markers of antimalarial resistance, including those associated with SP and DP resistance, among parasitemic children with sickle cell anemia randomized to receive monthly SP vs. monthly DP+SP.
|
Busia, Selected parishes
|
Uganda |
2025-10-29 15:55:44 |
2028-10-29 |
232 children with sickle cell anemia |
Aged 2-10 years children with sickle cell anemia |
Thrasher Research Fund |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Kyambadde Ronald
ID: UNCST-2025-R016678
|
HIGH DOSE VS STANDARD DOSE CAFFEINE THERAPY FOR APNEA OF PREMATURITY: A RANDOMISED CONTROL TRIAL.
REFNo: HS5776ES
To compare the efficacy and safety of high-dose caffeine citrate (loading dose 40 mg/kg/day, and maintenance of 20mg/kg/day), versus standard dose (loading dose of 20 mg/kg/day, maintenance of 10mg/kg/day), in preventing the occurrence and reducing the frequency of apneas among preterm infants ≤ 34 weeks’ gestation with Apnea Of Prematurity in the first 7 days of life.
Specific Objectives
1. To determine the effect of high dose compared to standard dose of caffeine on the incidence of apnea of prematurity among preterm babies at St. Francis Hospital, Nsambya, and Uganda
Martyrs’ Hospital Lubaga.
2. To determine the side effects of high dose compared to standard dose caffeine in preterm infants.
|
Kampala, Nsambya
Kampala, Lubaga
|
Uganda |
2025-10-21 9:08:50 |
2028-10-21 |
122 participants |
preterm babies born at the study sites during the study period with a New Ballard score ≤ 34 weeks |
no sponsorship |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Flavia Matovu Kiweewa
ID: UNCST-2021-R013337
|
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure
Prophylaxis in Women
REFNo: HS6666ES
To evaluate the efficacy of MK-8527 qm
compared to FTC/TDF qd for the
prevention of HIV-1 infection as assessed
by the incidence rate per year of adjudicated
HIV-1 infections.
Hypothesis: MK-8527 qm is superior to
FTC/TDF qd with respect to the hazard
ratio for HIV-1 infecti
|
Mityana,
Kalangala,
Kampala,
Masaka,
Wakiso,
|
Uganda |
2025-10-16 17:51:09 |
2028-10-16 |
Approximately 4580 participants |
16 to 30 years of age |
Merck Sharp & Dohme LLC |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Helen Byakwaga
ID: UNCST-2019-R001168
|
A Phase III/IV factorial randomised double-blind trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin/ezetimibe versus pitavastatin, in patients with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk (Optimising metabolic management on integrase-based antiretroviral therapy – the OPTIMAR Study)
REFNo: HS5819ES
To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe from baseline to 48 weeks on: fasting lipids, cardiovascular disease risk assessment measures; inflammatory biomarkers; and safety and tolerability,To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on: intermediate markers of cardiovascular disease risk; cardiovascular disease risk assessment measures; clinical consequences of increased body weight; and safety and tolerability of dapagliflozin,To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe on LDL concentration change from baseline to week 24,To assess the impact of dapagliflozin vs. placebo on absolute weight change from baseline to week 24,The overall objective of the study is to examine the impact of dapagliflozin vs. placebo on metabolic parameters in PWH with high metabolic risk who are on INSTI-based ART.,
|
Kampala, Mulago I
|
Uganda |
2025-09-30 14:11:23 |
2028-09-30 |
30 at the Infectious Diseases Institute Kampala |
All adults aged 40-75 years, both female, all tribes will be included. |
The Kirby Institute |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joweria Nambooze
ID: UNCST-2019-R001118
|
Effect of consumption of cape gooseberries on blood glucose control among patients with type 2 diabetes mellitus in Kampala, Uganda
REFNo: HS6017ES
To evaluate patient adherence to dietary interventions involving gooseberries,To compare change in glycated hemoglobin (HbA1c) levels among T2DM patients consuming gooseberries regularly as part of their diet with those following a regular diet. ,To assess the effect of regular consumption of gooseberries on fasting blood glucose levels in T2DM patients.,To evaluate the effect of cape gooseberries on blood glucose control among patients with T2DM in Kampala, Uganda.,
|
Kampala, All parishes
|
Uganda |
2025-09-26 18:13:11 |
2028-09-26 |
200 |
The study will include adult patients with T2DM who attend the Saint (St) Francis Nsambya hospital diabetes clinic and the Mulago hospital diabetes clinic in Kampala. Convenience sampling will be used to select patients from these clinics who meet specific study criteria and are readily accessible. The two study sites will be purposively selected due to having established T2DM clinics, high patient volume, diverse population and proper patient records. However, the study participants will be randomly allocated to the study arms. |
Kyambogo University |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Patrick Okema
ID: UNCST-2025-R019099
|
Insulin storage in low resource settings, impact on the glycated hemoglobin.
REFNo: HS6078ES
To determine the modalities of insulin storage in children and adolescents with T1D in low resource settings and the effects on their Hemoglobin A1C (HbA1C) in northern Uganda
|
Gulu, All parish
Amuru, All parish
Nwoya, All parish
Omoro, All parish
|
Uganda |
2025-09-26 18:07:55 |
2028-09-26 |
60 - 100 |
Children and young adolescent with Type1 diabetes registered and is receiving care at the Gulu Regional Referral Hospital under the age of 23 years |
Sonia Nabeta Foundation |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jef VanPuyenbroeck
ID: UNCST-2025-R017911
|
Monitoring anthelmintic resistance in goats in Nwoya District, Uganda
REFNo: A617ES
Main objective:
To assess the efficacy of anthelmintics commonly used by goat farmers in Nwoya district.
Specific Objectives:
1. To determine the prevalence of GIN infesting goats in Nwoya district.
2. To determine nematode species infesting goats in Nwoya district, through coproculture and molecular speciation.
3. To compare the expenses to perform routine FECRT, with McMaster and Mini-FLOTAC, for monitoring anthelmintic resistance in Uganda.
4. To assess the efficiency of survey designs and fecal egg count methods to determine drug efficacy at a certain cost and endemicity.
|
Nwoya, All
Nwoya, All
Nwoya, All
|
Belgium |
2025-09-26 18:06:25 |
2028-09-26 |
383 |
All goat herds, kept for livelihood purposes, in Nwoya District will be considered to be included in this study.
|
Ghent University |
Agricultural Sciences |
Clinical Trial |
Degree Award |
|
Adoke Yeka
ID: UNCST-2021-R004300
|
An open-label, randomised, controlled, non-inferiority trial to compare the efficacy, safety and tolerability of a fixed dose Triple Artemisinin-based Combination Therapy (TACT) artemether-lumefantrine-amodiaquine versus first-line Artemisinin-based Combination Therapies (ACTs) for the treatment of uncomplicated Plasmodium falciparum malaria
REFNo: HS6344ES
To compare the efficacy of ALAQ vs AL and ALAQ vs ASAQ as defined by the 28-day PCR corrected adequate clinical and parasitological response (ACPR).
|
Tororo, Selected parishes
Busia, Selected parishes
|
Uganda |
2025-09-26 17:41:17 |
2028-09-26 |
1680 |
Male or female Participants with acute uncomplicated P. falciparum malaria |
University of Oxford |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Robert Ssekitoleko
ID: UNCST-2019-R001716
|
A Feasibility and Safety Study of the KeySuite Laparoscopic Devices for Cancer Diagnosis in Uganda
REFNo: SIR493ES
1. To evaluate potential safety issues associated with the use of the KeyScope in patients with intra-abdominal cancers or suspected cancers .
2. To determine the clinical performance of the KeyScope in viewing tissue masses in the abdomen.
3. To determine the clinical performance of the KeyLoop in retraction of the abdominal wall during laparoscopic surgery
4. To determine the acceptability of KeySuite laparoscopic devices in aiding to obtain laparoscopic biopsies
|
Kampala, Mulago II
|
Uganda |
2025-09-26 17:12:49 |
2028-09-26 |
12 |
The study is targeting 12 adult patients with cancer advised for an intra-abdominal biopsy to be collected for confirmatory. The study will target patients aged between 18 and 60 years. |
National Institute of Health |
Engineering and Technology |
Clinical Trial |
Non-degree Award |
|
Catriona Waitt John
ID: UNCST-2019-R001068
|
Drug Optimisation for LMICs in Pregnant HIV mothers and their INfants: temporary switch to CAB/RPV long acting injections in postpartum period
REFNo: HS5982ES
To characterise drug exposure in breast milk, and drug transfer to infants through breastfeeding, as well as infant drug elimination.
To characterise the elimination of CAB/RPV by describing PK profiles of IM CAB/RPV LA after last injection between 48 and 96 weeks.
To establish strategies on how to safely re-establish oral ART after discontinuation of IM CAB/RPV LA at 48 weeks and switch back to daily oral ART.
To explore early postpartum PK of CAB/RPV in maternal plasma and breastmilk.
To demonstrate antiviral activity and impact on retention in HIV care of temporarily switching to CAB/RPV LA compared with continuation of daily oral ART over 48 weeks.,
|
Kampala, Kampala
|
UK |
2025-09-17 13:21:16 |
2028-09-17 |
309 |
Consenting pregnant women living with HIV |
University of CapeTown |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Ronald Bisegerwa
ID: UNCST-2022-R011022
|
Accuracy of Pulse Oximeters with Profound Hypoxia
REFNo: HS6506ES
To generate two to three evidence-based recommendations to regulatory and procurement bodies within six months of study completion to guide pulse oximeter selection for diverse populations.,To collect and contribute data on pulse oximeter accuracy across diverse skin tones to an open-access device performance database by the study’s end, enabling manufacturers to refine pulse oximeter technology and ensure equitable performance across all skin tones, especially in low-resource settings.,To replicate the UCSF Hypoxia Lab in Uganda by establishing a fully equipped and operational facility within a year to evaluate pulse oximeter accuracy across diverse skin tones and hypoxia levels.,To evaluate the accuracy of pulse oximeters under controlled hypoxic conditions in a diverse population in Uganda, with a focus on understanding and addressing disparities in device performance related to skin pigmentation.,
|
Kampala, Kololo
|
Uganda |
2025-09-12 17:03:12 |
2028-09-12 |
432 |
This study will be done on healthy male or female participants between the ages of 18-50 years. |
Association of Anesthesiologists of Uganda |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pauline Amuge Mary
ID: UNCST-2023-R005532
|
LC-REVITALIZE – A Long Covid Repurposed Drug Study
REFNo: HS6370ES
-To assess the efficacy of repurposed drugs compared to their
respective placebos in reducing standardized symptom severity scores
in participants with Long Covid.
-To compare the symptom burden (e.g., anxiety, depression, overall
well-being) in participants with Long Covid treated with repurposed
drugs versus their respective placebos.
- To assess whether symptom burden worsens in participants with Long
Covid treated with study drugs versus placebo, specifically when
symptoms are reported across multiple scales.
- To assess changes in exercise capacity over time of participants with
Long Covid treated with study drugs versus their respective placebos.
- To measure specific Long Covid pathophysiological biomarkers of study
drugs versus their respective placebos.
|
Wakiso, Sabagabo
|
Uganda |
2025-09-12 17:00:13 |
2028-09-12 |
384 |
Adults, male and female with Long COVID |
Dr. Douglas D. Fraser- Western University |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
alice namatovu
ID: UNCST-2025-R017415
|
EVALUATION OF THE EFFECTIVENESS OF BACTERIOPHAGE COCKTAILS AGAINST MULTI-DRUG-RESISTANT BACTERIA ON PATIENTS WITH DIABETIC FOOT ULCERS ATTENDING SELECTED REFERRAL HOSPITALS IN UGANDA
REFNo: HS5652ES
Main objective:
To assess the efficacy of bacteriophages in the management of diabetic foot wounds/ulcers in animal models and among patients attending the selected referral hospitals in Uganda.
Specific Objectives
i) To determine the biological and genotypic characteristics of lytic bacteriophages against the MDR- bacteria isolated from diabetic wounds of patients.
ii) To determine the virulence genes of the bacteria isolated from DFU patients and those genes associated with antimicrobial resistance.
iii) Determine the phage receptor genes on the MDR bacteria isolated from DFU patients.
iv). To evaluate the effectiveness of the identified Bacteriophage preparation/cocktail in the healing of induced diabetic wounds in mice.
v). To evaluate the effectiveness of the identified bacteriophage preparation/cocktail in the healing of diabetic foot wounds on patients in selected referral hospitals in Uganda.
|
Kampala, Namirembe
Kampala, Nsambya
|
Uganda |
2025-09-12 16:14:57 |
2028-09-12 |
138 human participants |
The study will be conducted on patients attending the selected regional referral hospitals in Uganda diagnosed with diabetes including those having diabetic foot ulcer/wounds that are not responding to antibiotic therapy, those with diabetes and not having diabetic foot and those without diabetes but having chronic wounds.
Inclusion and exclusion criteria: All Patients of 18 years and above, male or female diagnosed with diabetes and willing to participate in the study will be included. Diabetic type will be determined clinically based on the diabetes control strategy used. Those depending on insulin for diabetes control since the time of diagnosis will be classified as having T1DM while those who had been controlled on oral anti-diabetic drugs with or without insulin will be categories as T2DM. One hundred and thirty-eight patients expected to participate in the study as cases are expected to have non traumatic DFU while the control group will include diabetic patients without DFU and non-diabetic patients with chronic foot wounds. The different groups will be matched for age and gender. The exclusion criteria will include pregnant women, patients with other diabetes other than types 1 and 2, and those with wounds limited to above the ankle joints.
|
Makerere Research and innovation Fund by the Ugandan Government |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Nazarius Tumwesigye Mbona
ID: UNCST-2019-R000664
|
WEB-BASED INTERVENTION FOR ALCOHOL AND SUBSTANCE ABUSE AMONG YOUNG UNIVERSITY STUDENTS
REFNo: SS1785ES
To assess feasibility and effectiveness of the web-based intervention for prevention and treatment of ASUD problems among youth 18-24 years attending Universities in Uganda,To develop a web-based intervention for prevention and treatment of ASUD problems among youth 18-24years attending Universities in Uganda,To establish the prevalence of ASUD problems among youth 18-24years in selected Universities,To contribute to the improvement of the quality of ASUD treatment services in Uganda among the youth through the development of a web-based intervention and assess its feasibility and effectiveness for the prevention and treatment of ASUD among University students in Uganda,
|
Kampala, Mulago
Mpigi, Nkozi
|
Uganda |
2025-09-09 8:17:25 |
2028-09-09 |
5000 |
Any student aged 18 – 24 years at any level of education from the following universities: Makerere University, Kyambogo University, Makerere University Business School (semi-independent public entity), Uganda Christian University, Uganda Martyrs University Nkozi, Kampala International University (KIU) and Ndejje University. |
Government of Uganda |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Adoke Yeka
ID: UNCST-2021-R004300
|
Randomised controlled trial to assess the efficacy of artemisinin combination therapies in a setting of emerging artemisinin resistance in Uganda.
REFNo: HS6327ES
To assess the 42-day clinical and parasitological efficacy of artemether-lumefantrine (AL) and pyronaridine-artesunate (PA) for the treatment of uncomplicated P. falciparum malaria in Uganda.
|
Arua, Selected parishes
Tororo, Selected parishes
|
Uganda |
2025-09-09 16:41:47 |
2028-09-09 |
150 patients on each treatment arm per site, 600 participants in total, (300 per site, AL: 150, PA: 150). |
Febrile patients aged 6 months to 10 years with confirmed uncomplicated P. falciparum malaria. |
Infectious Diseases Research Collaboration (IDRC) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Fred Bulamba
ID: UNCST-2020-R014888
|
PErioperative respiratory care and outcomes for patieNts Undergoing hIgh risk abdomiNal surgery
REFNo: HS2178ES
To explore the cost-effectiveness of the different treatment combinations in reducing pneumonia and SSI at pre-selected centres.,To assess the impact of both interventions on postoperative mortality at 30-days, and the effect of 80-100% FiO2 only on the re-operation rate at 30 days after surgery.,To assess whether (1) preoperative 0.2% chlorhexidine mouthwash reduces the rate of postoperative pneumonia at 30-days compared to no mouthwash, and (2) 80-100% FiO2 used during surgery reduces the rate of postoperative SSI at 30-days compared to 21-35% FiO2, amongst patients aged 10 years or over undergoing elective or emergency midline laparotomy, with an anticipated abdominal incision of ≥5cm, for any indication except caesarean section.,
|
Mbale, Hospital cell
|
Uganda |
2025-08-28 10:15:49 |
2028-08-28 |
1000 (for Uganda only) |
Patients above 10 years undergoing abdominal surgery |
Dr Birgit Whitman |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Edwin Nuwagira
ID: UNCST-2021-R013488
|
EFFICACY AND TOLERABILITY OF SHORT-COURSE INTERMITTENT INTRAVENOUS LIPOSOMAL AMPHOTERICIN B VERSUS ORAL POSACONAZOLE FOR CHRONIC PULMONARY ASPERGILLOSIS: A PHASE IIA, PROSPECTIVE, MULTI-CENTRE, RANDOMIZED, CONTROLLED, OPEN-LABEL, FEASIBILITY TRIAL
REFNo: HS6400ES
5. Assess recruitment and retention of patients with CPA on a trial to inform design and sample size for a definitive efficacy trial.,4. To assess adherence to posaconazole therapy,3. To evaluate the utility of different trial endpoints (change in Aspergillus IgG antibody titer, radiological improvement, step test and weight) across groups.,2. To compare 12-month all-cause mortality in each arm,1. To measure emergence of isolates of Aspergillus with resistance/reduced susceptibility to posaconazole in both arms. ,1. Compare the efficacy and tolerability of 1) short course, high dose of intravenous liposomal amphotericin B, 2) short course, high dose of intravenous liposomal amphotericin B followed by daily posaconazole, or 3) posaconazole alone for the treatment of CPA for 6 months.,
|
Mbarara, Medical cell
Gulu, Medical cell
Kampala, Salama road
|
Uganda |
2025-08-26 13:48:03 |
2028-08-26 |
120 |
Adults, age > or = to 18 years
All Ugandan tribes living in Ankole/Kigezi sub region
Both women and men |
Fungal Infection Trust |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
RACHEL LUWAGA
ID: UNCST-2024-R003040
|
EFFECT OF A DISCHARGE EDUCATION INTERVENTION ON PREVENTION OF
PUERPERAL SEPSIS AMONG MOTHERS WHO HAVE DELIVERED BY CESAREAN
SECTION IN SOUTHWESTERN UGANDA
REFNo: HS5504ES
. To determine the prevalence, factors, and outcomes associated with readmission of
mothers who had undergone cesarean section delivery due to sepsis in Mbarara Regional
Referral Hospital
2. To describe the experiences and practices of mothers in the prevention of puerperal sepsis
post cesarean section in Mbarara Regional Referral Hospital
3. To explore the barriers and facilitators to the provision of discharge instructions
regarding puerperal sepsis prevention for mothers who have delivered by cesarean
section in Mbarara Regional Referral Hospital
4. To determine the effect of a discharge education intervention in the prevention of puerperal of
sepsis in post-cesarean section mothers.
|
Mbarara, Kamukuzi
|
Uganda |
2025-08-18 13:28:40 |
2028-08-18 |
8-10 mother with peurperal sepsis,8-10 health workers, 130 pr |
mothers diagnosed with puerperal sepsis after cesarean section delivery
Health workers working on the obstetric and gynecology ward
Primipara mothers who have delivered by cesarean section |
self sponsorship |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
